UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 8,774 Shares of Iradimed Corporation (NASDAQ:IRMD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Iradimed Corporation (NASDAQ:IRMD - Free Report) by 91.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,359 shares of the medical equipment provider's stock after purchasing an additional 8,774 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.14% of Iradimed worth $1,010,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Iradimed by 4.4% during the 4th quarter. Vanguard Group Inc. now owns 536,811 shares of the medical equipment provider's stock valued at $29,525,000 after purchasing an additional 22,762 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Iradimed by 3.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 227,257 shares of the medical equipment provider's stock worth $12,499,000 after acquiring an additional 7,606 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Iradimed by 17.9% in the fourth quarter. Geode Capital Management LLC now owns 222,772 shares of the medical equipment provider's stock worth $12,255,000 after purchasing an additional 33,879 shares in the last quarter. Northern Trust Corp boosted its holdings in Iradimed by 7.3% in the fourth quarter. Northern Trust Corp now owns 143,069 shares of the medical equipment provider's stock worth $7,869,000 after purchasing an additional 9,722 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Iradimed by 94.1% in the fourth quarter. Bank of New York Mellon Corp now owns 100,108 shares of the medical equipment provider's stock worth $5,506,000 after purchasing an additional 48,534 shares in the last quarter. Institutional investors own 92.34% of the company's stock.

Iradimed Stock Performance

Shares of NASDAQ IRMD traded down $1.39 during mid-day trading on Friday, hitting $58.17. 39,461 shares of the stock were exchanged, compared to its average volume of 42,983. The company has a market cap of $739.63 million, a P/E ratio of 38.78 and a beta of 0.92. The stock's fifty day simple moving average is $54.01 and its two-hundred day simple moving average is $54.89. Iradimed Corporation has a twelve month low of $42.11 and a twelve month high of $63.29.

Iradimed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 30th. Stockholders of record on Tuesday, May 20th were issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend was Tuesday, May 20th. Iradimed's payout ratio is 43.87%.

Wall Street Analyst Weigh In

IRMD has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Iradimed from a "buy" rating to a "strong-buy" rating in a report on Tuesday, May 6th. Roth Mkm reissued a "buy" rating and issued a $72.00 price target (up previously from $60.00) on shares of Iradimed in a research report on Friday, February 14th.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.